The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice
Open accessAbstract
Dominantly inherited mutations in leucine-rich repeat kinase 2 (LRRK2) are a common genetic cause of Parkinson's disease (PD). The importance of the R1441 residue in the pathogenesis is highlighted by the identification of three distinct missense mutations. To investigate the pathogenic mechanism underlying LRRK2 dysfunction, we generated a knockin (KI) mouse in which the R1441C mutation is expressed under the control of the endogenous regulatory elements. Homozygous R1441C KI mice appear grossly normal and exhibit no dopaminergic (DA) neurodegeneration or alterations in steady-state levels of striatal dopamine up to 2 years of age. However, these KI mice show reductions in amphetamine (AMPH)-induced locomotor activity and stimulated catecholamine release in cultured chromaffin cells. The introduction of the R1441C mutation also impairs dopamine D2 receptor function, as suggested by decreased responses of KI mice in locomotor activity to the inhibitory effect of a D2 receptor agonist, quinpirole. Furthermore, the firing of nigral neurons in R1441C KI mice show reduced sensitivity to suppression induced by quinpirole, dopamine, or AMPH. Together, our data suggest that the R1441C mutation in LRRK2 impairs stimulated dopamine neurotransmission and D2 receptor function, which may represent pathogenic precursors preceding dopaminergic degeneration in PD brains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Neuropathology of Parkinsonʼs Disease
Forno, L. S. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,465
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 2×
“Recent in vitro studies suggest that mutations in LRRK2 (R1441C, G2019S) cause increases in its kinase activity (9, 10), which mediates neuronal toxicity and is regulated by the GTPase domain in a GTP-dependent manner (10–13).”
Modulation of neurotransmitter release by presynaptic autoreceptors
Starke, K., Gothert, M., & Kilbinger, H. (1989) · Physiological Reviews · doi:10.1152/physrev.1989.69.3.864 · Cited by 925
Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308947200 · Cited by 913
Self-citationSlower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Distinct functions of the two isoforms of dopamine D2 receptors
Usiello, A., Baik, J.-H., Rougé-Pont, F., Picetti, R., Dierich, A., LeMeur, M., Piazza, P. V., & Borrelli, E. (2000) · Nature · doi:10.1038/35041572 · Cited by 717
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2006) · Nature Neuroscience · doi:10.1038/nn1776 · Cited by 619
Lacey, M. G., Mercuri, N. B., & North, R. A. (1987) · The Journal of Physiology · doi:10.1113/jphysiol.1987.sp016787 · Cited by 614 · cited 1×
“The inhibitory effect of dopamine on nigral neurons is mediated specifically by somatodendritic D2 autoreceptors, because it is fully prevented by D2 receptor antagonists (29) and is absent in D2R (cid:8) / (cid:8) mice (32).”
The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology
MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., & Abeliovich, A. (2006) · Neuron · doi:10.1016/j.neuron.2006.10.008 · Cited by 564
Impaired dopamine release and synaptic plasticity in the striatum of PINK1 -deficient mice
Kitada, T., Pisani, A., Porter, D. R., Yamaguchi, H., Tscherter, A., Martella, G., Bonsi, P., Zhang, C., Pothos, E. N., & Shen, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702717104 · Cited by 540
Self-citationGoldberg, M. S., Pisani, A., Haburcak, M., Vortherms, T. A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.041 · Cited by 538
Self-citationMutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease
Li, Y., Liu, W., Oo, T. F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2349 · Cited by 536
West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.-L., Dawson, V. L., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl471 · Cited by 533
Localization of LRRK2 to membranous and vesicular structures in mammalian brain
Biskup, S., Moore, D. J., Celsi, F., Higashi, S., West, A. B., Andrabi, S. A., Kurkinen, K., Yu, S., Savitt, J. M., Waldvogel, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.21019 · Cited by 511
Smith, W. W., Pei, Z., Jiang, H., Moore, D. J., Liang, Y., West, A. B., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508052102 · Cited by 424
Burst Firing in Dopamine Neurons Induced by N -Methyl-D-aspartate: Role of Electrogenic Sodium Pump
Johnson, S. W., Seutin, V., & North, R. A. (1992) · Science · doi:10.1126/science.1329209 · Cited by 419
Calcium signaling and exocytosis in adrenal chromaffin cells
García, A. G., García-De-Diego, A. M., Gandía, L., Borges, R., & García-Sancho, J. (2006) · Physiological Reviews · doi:10.1152/physrev.00039.2005 · Cited by 349
LRRK2 regulates synaptic vesicle endocytosis
Shin, N., Jeong, H., Kwon, J., Heo, H. Y., Kwon, J. J., Yun, H. J., Kim, C.-H., Han, B. S., Tong, Y., Shen, J., et al. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.02.015 · Cited by 329
Self-citationA Drosophila model for LRRK2 -linked parkinsonism
Liu, Z., Wang, X., Yu, Y., Li, X., Wang, T., Jiang, H., Ren, Q., Jiao, Y., Sawa, A., Moran, T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708452105 · Cited by 279
An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family
Funayama, M., Hasegawa, K., Ohta, E., Kawashima, N., Komiyama, M., Kowa, H., Tsuji, S., & Obata, F. (2005) · Annals of Neurology · doi:10.1002/ana.20484 · Cited by 264
Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T., & Iwatsubo, T. (2007) · Biochemistry · doi:10.1021/bi061960m · Cited by 263
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*
Berg, D., Schweitzer, K. J., Leitner, P., Zimprich, A., Lichtner, P., Belcredi, P., Brüssel, T., Schulte, C., Maass, S., Nägele, T., et al. (2005) · Brain · doi:10.1093/brain/awh666 · Cited by 261
Lrrk2 pathogenic substitutions in Parkinson's disease
Mata, I. F., Kachergus, J. M., Taylor, J. P., Lincoln, S., Aasly, J., Lynch, T., Hulihan, M. M., Cobb, S. A., Wu, R.-M., Lu, C.-S., et al. (2005) · Neurogenetics · doi:10.1007/s10048-005-0005-1 · Cited by 231
Robertson, S. D., Matthies, H. J. G., & Galli, A. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8053-4 · Cited by 205
Properties of the Hyperpolarization‐activated Cation Current lh in Rat Midbrain Dopaminergic Neurons
Mercuri, N. B., Bonci, A., Calabresi, P., Stefani, A., & Bernardi, G. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00342.x · Cited by 204
(1997) · Neuroscience · doi:10.1016/s0306-4522(97)00135-8 · Cited by 198
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
The Italian Parkinson Genetics Network, Di Fonzo, A., Tassorelli, C., De Mari, M., Chien, H. F., Ferreira, J., Rohé, C. F., Riboldazzi, G., Antonini, A., Albani, G., et al. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201539 · Cited by 174
A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations
Zabetian, C. P., Samii, A., Mosley, A. D., Roberts, J. W., Leis, B. C., Yearout, D., Raskind, W. H., & Griffith, A. (2005) · Neurology · doi:10.1212/01.wnl.0000172630.22804.73 · Cited by 164
The DRD2 gene in psychiatric and neurological disorders and its phenotypes
Noble, E. P. (2000) · Pharmacogenomics · doi:10.1517/14622416.1.3.309 · Cited by 160
Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila
Lee, S. B., Kim, W., Lee, S., & Chung, J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.156 · Cited by 159
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinsonʼs disease
Jenner, P. G. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200312001-00002 · Cited by 137
LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?
Taylor, J. P., Mata, I. F., & Farrer, M. J. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.12.004 · Cited by 108
Pothos, E. N., Mosharov, E. V., Liu, K., Setlik, W., Haburčák, M., Baldini, G., Gershon, M. D., Tamir, H., & Sulzer, D. (2002) · The Journal of Physiology · doi:10.1113/jphysiol.2002.018630 · Cited by 103
Self-citationNeher, E. (2006) · Pflügers Archiv · doi:10.1007/s00424-006-0143-9 · Cited by 98
Gnegy, M. E., Khoshbouei, H., Berg, K. A., Javitch, J. A., Clarke, W. P., Zhang, M., & Galli, A. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.137 · Cited by 96
Dopamine D2 Receptor-Mediated Inhibition of Dopaminergic Neurons in Mice Lacking D2L Receptors
Centonze, D., Usiello, A., Gubellini, P., Pisani, A., Borrelli, E., Bernardi, G., & Calabresi, P. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00367-6 · Cited by 93
Self-citationAbsence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice
Yamaguchi, H., & Shen, J. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-10 · Cited by 83
Self-citationKantor, L., Hewlett, G. H. K., Park, Y. H., Richardson-Burns, S. M., Mellon, M. J., & Gnegy, M. E. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29628-2 · Cited by 77
Skipper, L. M., Li, Y., Bonnard, C., Ratnagopal, P., Yih, Y., Chua, E., Sung, W.-K. K., Tan, L. C. S., Wong, M. C., Tan, E., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi376 · Cited by 76
Responses of rat substantia nigra compacta neurones to L‐DOPA
Mercuri, N. B., Calabresi, P., & Bernardi, G. (1990) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1990.tb15792.x · Cited by 50
Neuroprotective Mechanisms of Antiparkinsonian Dopamine D2-Receptor Subfamily Agonists
Kitamura, Y., Taniguchi, T., Shimohama, S., Akaike, A., & Nomura, Y. (2003) · Neurochemical Research · doi:10.1023/a:1023207222944 · Cited by 44
Meloni, E. G., & Davis, M. J. (2000) · Psychopharmacology · doi:10.1007/s002130000474 · Cited by 17
Cited by
Genetic Animal Models of Parkinson's Disease
Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.034 · Cited by 823
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
Jiang, T., Sun, Q., & Chen, S. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.07.005 · Cited by 586
Lin, X., Parisiadou, L., Gu, X.-L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.-X., Yang, W.-J., Ding, J., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.006 · Cited by 518
RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk
MacLeod, D. A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B. D., Marder, K. S., Honig, L. S., Clark, L. N., Small, S. A., et al. (2013) · Neuron · doi:10.1016/j.neuron.2012.11.033 · Cited by 516
Metadata
- Authors
- Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E. N., & Shen, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-08-25
- Volume
- 106
- Issue
- 34
- Pages
- 14622-14627
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2091996540
- Cited by
- 304
- References
- 45
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.